Dare Bioscience Inc (DARE)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$0.72+0.50%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Broken: Primary pillar broken — Revenue growth to at least $7.4M in FY27: rev $0.2M vs $7.4M target.
Dare Bioscience is launching new women's health products that could grow revenue. Analysts expect revenue to rise from $1.8M this quarter to $7.4M next year. Losses are narrowing, with EPS improving from -$0.95 this year to -$0.51 next year. The company is working to stabilize after recent equity raises.
The company is still loss-making with negative free cash flow and high risk. Revenue growth is uncertain without clear guidance. Recent equity sales dilute shareholders and signal funding pressure. The stock is down 37% from its high, showing weak investor confidence.
The price is about 26% above our fair value near $1.61, implying 8% growth over 3 years. This premium may be too high given ongoing losses and uncertain revenue growth. Our view is more cautious than the current price.
Breaks if: Company announces new large equity offerings within next 4 quarters
Breaks if: EPS loss worsens beyond -$0.95 in FY26 or fails to improve toward -$0.51 in FY27
Breaks if: revenue falls below $2.1M in FY26 or fails to grow toward $7.4M in FY27
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is navigating a volatile management landscape while attempting to launch new products and advance its clinical pipeline.
The current valuation suggests a premium compared to peers, indicating that the market has high expectations for future growth. However, recent performance has shifted from the top half to the bottom half of its industry, suggesting that these expectations may be overly optimistic.
Management is focused on launching new products and advancing clinical studies, but the recent financial performance has been neutral. The near-term risk remains elevated, with a 33% probability of missing expectations, particularly given the company's smaller size and the high miss rate in its industry.
The thesis hinges on the company's ability to successfully launch its new products and maintain momentum in the healthcare sector. Key scenarios include potential negative impacts from guidance cuts or economic downturns, as well as positive influences from strong performances by sector leaders.
Over the next 1 to 3 years, DARE's outlook is uncertain, with a mix of opportunities and risks that could significantly impact its trajectory. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. Recent financial performance dropped from the top half to the bottom half of its industry. This change signals a weakened reason to own the stock. Additionally, the company missed earnings expectations, indicating potential cash flow issues.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.